Puma Biotechnology, Inc.

NasdaqGS:PBYI Stock Report

Market Cap: US$135.0m

Puma Biotechnology Past Earnings Performance

Past criteria checks 5/6

Puma Biotechnology has been growing earnings at an average annual rate of 62.7%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been declining at an average rate of 2.7% per year. Puma Biotechnology's return on equity is 32.7%, and it has net margins of 9.5%.

Key information

62.7%

Earnings growth rate

63.1%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-2.7%
Return on equity32.7%
Net Margin9.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest

Nov 14
Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest

We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

May 09
We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

Recent updates

Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward

Dec 16

Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest

Nov 14
Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest

Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?

Sep 07
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?

Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop

Aug 15
Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop

The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%

Jun 07
The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%

Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today

Jun 05
Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today

We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

May 09
We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

Puma Biotechnology: A Story In Flux Heading Into Mid-2024

May 05

Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

Apr 10
Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Mar 01
There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Dec 27
Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Sep 08
Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

Apr 17
Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Dec 14
We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib

Sep 20

Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt

Sep 05
Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt

Revenue & Expenses Breakdown

How Puma Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:PBYI Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24244238353
30 Jun 2421998952
31 Mar 24227158951
31 Dec 23236228950
30 Sep 2322949751
30 Jun 23230-29851
31 Mar 2323559450
31 Dec 2222809252
30 Sep 22218108753
30 Jun 22207-349060
31 Mar 22201-4910867
31 Dec 21253-2911672
30 Sep 21250-4812282
30 Jun 21255-3512686
31 Mar 21272-2711692
31 Dec 20225-6011898
30 Sep 20235-56120104
30 Jun 20241-42122110
31 Mar 20224-82126123
31 Dec 19272-76140133
30 Sep 19280-95151141
30 Jun 19287-92148147
31 Mar 19284-99155154
31 Dec 18251-114146165
30 Sep 18202-147136177
30 Jun 18145-210140190
31 Mar 1894-243125200
31 Dec 1728-292107208
30 Sep 176-30192214
30 Jun 170-28974216
31 Mar 170-27861217
31 Dec 160-27654223
30 Sep 160-26547219
30 Jun 160-26042219
31 Mar 160-25835224
31 Dec 150-23932208
30 Sep 150-22530196
30 Jun 150-20025176
31 Mar 150-17524151
31 Dec 140-14219123
30 Sep 140-1101496
30 Jun 140-891376
31 Mar 140-631152

Quality Earnings: PBYI has high quality earnings.

Growing Profit Margin: PBYI's current net profit margins (9.5%) are higher than last year (1.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: PBYI has become profitable over the past 5 years, growing earnings by 62.7% per year.

Accelerating Growth: PBYI's earnings growth over the past year (525.3%) exceeds its 5-year average (62.7% per year).

Earnings vs Industry: PBYI earnings growth over the past year (525.3%) exceeded the Biotechs industry 16.6%.

Return on Equity

High ROE: Whilst PBYI's Return on Equity (32.69%) is high, this metric is skewed due to their high level of debt.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 14:29
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Puma Biotechnology, Inc. is covered by 17 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Geoffrey MeachamBofA Global Research
Alethia YoungCantor Fitzgerald & Co.